U.S. Biosimilars Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Filgrastim & Pegfilgrastim, Monoclonal Antibodies, and Others), By Disease Indication (Cancer, Autoimmune Diseases {Arthritis, Psoriasis, Neutropenia, and Others}, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2022-2029

Last Updated: February 03, 2025 | Format: PDF | Report ID: FBI100990

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2018-2029
Base Year	2021
Estimated Year	2022
Forecast Period	2022-2029
Historical Period	2018-2020
Unit	Value (USD billion)
Segmentation	By Drug Class, Disease Indication, and Distribution Channel
Segmentation	By Drug Class Filgrastim & Pegfilgrastim Monoclonal Antibodies Others
	By Disease Indication Cancer Autoimmune Diseases Arthritis Psoriasis Neutropenia Others Others
	By Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies